Physician profile
Michelle Phillips
NPI 1174976716
$6,287.13
in general payments reported to CMS, 2019-2025
34 companies · $1,207 in 2025
The $1,207 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $837 · 2022: $1,285 · 2023: $1,725 · 2024: $1,233 · 2025: $1,207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,033 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,032.77 |
| Education | $132.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,295.16 | 2021-2025 | |
| Lilly USA, LLC | $815.66 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $710.16 | 2021-2025 | |
| Abbott Laboratories | $426.28 | 2022-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $398.01 | 2023-2025 | Veozah |
| Glaxosmithkline, LLC. | $363.27 | 2022-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Biohaven Pharmaceutical Holding Company LTD. | $342.97 | 2022 | |
| Novo Nordisk INC | $276.36 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Biohaven Pharmaceuticals, INC. | $254.15 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $220.72 | 2021-2024 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $195.58 | 2024-2025 | Airsupra, Farxiga |
| Amgen INC. | $188.45 | 2021-2024 | Repatha, Evenity, Prolia |
| Organon LLC | $164.28 | 2022-2024 | Nexplanon |
| Axsome Therapeutics, INC. | $110.14 | 2025 | Auvelity, Symbravo |
| Boston Scientific Corporation | $67.65 | 2022-2025 | Watchman Flx |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $47.63 | 2024 | Inspire |
| Otsuka America Pharmaceutical, INC. | $44.71 | 2024-2025 | Rexulti |
| Daiichi Sankyo INC. | $39.73 | 2022 | |
| Dexcom, INC. | $36.94 | 2023-2024 | Dexcom G6 Transmitter |
| Lundbeck LLC | $34.65 | 2022-2025 | Rexulti |
| Avion Pharmaceuticals | $27.31 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $24.62 | 2025 | Fanapt |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.28 | 2021 | |
| Corcept Therapeutics | $20.75 | 2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $18.82 | 2025 | |
| Medtronic, INC. | $18.42 | 2025 | Abre |
| Novartis Pharmaceuticals Corporation | $18.19 | 2021 | |
| Exact Sciences Corporation | $17.18 | 2023 | Cologuard Collection Kit |
| Optinose US, INC. | $15.66 | 2022 | |
| Seqirus USA INC | $15.52 | 2025 | Fluad, Flucelvax |
| Idorsia Pharmaceuticals US INC | $14.69 | 2023 | Quviviq |
| Abiomed | $14.28 | 2023 | Impella |
| Arbor Pharmaceuticals, INC. | $13.83 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $12.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.